Actively Recruiting
Phase 1 Study of BMS-986463 Drug for Treating Advanced High-grade Serous Ovarian, Uterine Serous, and Non-small Cell Lung Cancers
Led by Bristol-Myers Squibb · Updated on 2026-07-20
240
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, and efficacy of increasing doses of the drug BMS-986463 in participants who have certain advanced malignant tumors, including high-grade serous ovarian carcinoma, uterine serous carcinoma, and non-small cell lung cancer. This Phase 11b study aims to understand how well participants tolerate the drug and to gather early information on its effects in these cancer types. Participants receive specified doses of BMS-986463 on predetermined days. The study includes a dose escalation phase where doses are gradually increased and a dose expansion phase to further evaluate the drug at selected doses. This first-in-human trial is conducted without randomization or blinding. During the study, participants will undergo biopsies before treatment and will be closely monitored for adverse events, including serious side effects and any events that may limit dosing. Researchers will measure drug levels in the body and evaluate tumor responses over a period of up to 108 weeks. Participants overall health and safety will be assessed frequently throughout the trial to gather comprehensive data on the drugs effects.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here